Gamma-Delta T Cell Donor Selection for Immunotherapy Efficacy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current γδT-based immunotherapies face limitations due to variable expansion capacity and functional instability of γδ T cells, leading to reduced efficacy in cancer treatment, primarily because of the high interindividual heterogeneity in γδ T cell expansion and dysfunction.
Innovation Solution
A method for selecting donors based on high expansion capacity of γδ T cells, involving assessment of Vδ2 Index Score, basal levels of Vδ2 T cells, immune phenotypes, and cytokine profiles to ensure optimal γδ T cell-based immunotherapy, along with the use of γδ TCR activators and TLR agonists for expanding and activating γδ T cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If γδ T cells are used for adoptive immunotherapy, then tumor cell recognition and destruction capability is improved, but interindividual heterogeneity in expansion capacity and functional stability causes variable treatment efficacy
Solution Approach 1:
The patent performs preliminary assessment of γδ T cell expansion capacity and functional characteristics in healthy donors before selecting them as sources for immunotherapy. This advance evaluation allows identification of donors with optimal cell properties, ensuring reliable treatment outcomes while accounting for interindividual heterogeneity. The preliminary characterization includes assessing expansion capacity, cytokine production, and cytotoxicity markers to predict therapeutic efficacy.
Solution Approach 2:
The patent changes the selection parameters for donor choice by establishing specific thresholds for γδ T cell characteristics such as expansion capacity, Vδ2 subset frequency, and functional marker expression. By adjusting these selection parameters based on empirical data, the method optimizes the probability of obtaining therapeutically effective cell products while accounting for natural variability among individuals.
2Quantity of substance
If γδ T cells are expanded using conventional methods, then cell quantity is increased, but functional instability and dysfunction reduce therapeutic effectiveness
Solution Approach 1:
The patent implements quality control feedback mechanisms by monitoring functional markers and expansion capacity throughout the cell expansion process. Cells are assessed for maintaining functional characteristics such as cytokine production capability and cytotoxicity markers during expansion. This feedback allows adjustment of expansion conditions to preserve functional stability while achieving adequate cell quantities for therapy.
Solution Approach 2:
The patent performs preliminary characterization of γδ T cells before expansion to establish baseline functional properties. This advance assessment allows selection of cell populations with optimal functional potential and enables comparison with post-expansion samples to ensure functional stability is maintained throughout the expansion process.
3Adaptability or versatility
If cancer patient-derived γδ T cells are used, then patient-specific immunity is achieved, but expansion capacity is lower and cytotoxicity is reduced
Solution Approach 1:
The patent introduces healthy donor γδ T cells as an intermediary source that can be used for allogeneic immunotherapy. These cells serve as a substitute for patient-derived cells, providing comparable or superior expansion capacity and cytotoxicity while still targeting patient-specific tumors. The healthy donor cells act as a mediator that overcomes the functional limitations of cancer patient-derived cells.
Solution Approach 2:
The patent inverts the conventional approach by using healthy donor cells instead of patient-derived cells for adoptive immunotherapy. This reversal of the donor selection strategy exploits the superior functional properties of healthy donor γδ T cells while still achieving patient-specific anti-tumor immunity through allogeneic cell transfer.
Data Source
AI summary
The present disclosure provides methods for selecting donors for γδT cell-based immunotherapy. The disclosure also provides methods for expanding and activating γδ T cells with improved cytotoxicity toward tumor cells and reduced T cell exhaustion. Pharmaceutical compositions comprising the expanded γδ T cells and methods of treatment are also provided.